Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack
- PMID: 18194418
- PMCID: PMC2327206
- DOI: 10.1111/j.1538-7836.2008.02902.x
Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack
Abstract
Background: A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS-13) may influence von Willebrand factor (VWF) levels and consequently the risk of myocardial infarction (MI). Moreover, ADAMTS-13 influences hemostatic plug formation in mouse models. We therefore studied their associations in the Glasgow MI Study (GLAMIS).
Methods and results: We measured ADAMTS-13 and VWF antigen levels by ELISAs in stored plasma from a case-control study of 466 MI cases and 484 age- and sex-matched controls from the same north Glasgow population. There was no correlation between ADAMTS-13 and VWF levels in cases or controls. ADAMTS-13 levels correlated positively with serum cholesterol and triglycerides and body mass index, and negatively with high-density lipoprotein-cholesterol. VWF levels correlated with age, fibrinogen and C-reactive protein. In multivariable analyses including risk factors, VWF correlated positively with risk of MI, and ADAMTS-13 correlated negatively with risk of MI. These associations were independent of each other. The association of ADAMTS-13 with risk of MI was observed only in multivariable analysis.
Conclusions: VWF and ADAMTS-13 levels were not associated in this study, and showed associations with MI risk in opposite directions but of similar strength. The association of ADAMTS-13 with MI is influenced by lipid levels, and consequently requires further investigation.
Similar articles
-
ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men.Blood. 2007 Mar 1;109(5):1998-2000. doi: 10.1182/blood-2006-07-038166. Epub 2006 Oct 19. Blood. 2007. PMID: 17053057
-
ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer.J Thromb Haemost. 2016 Feb;14(2):306-15. doi: 10.1111/jth.13205. Epub 2016 Jan 25. J Thromb Haemost. 2016. PMID: 26589836
-
Evaluation of von Willebrand factor and ADAMTS-13 antigen and activity levels in sickle cell disease patients in Kuwait.J Thromb Thrombolysis. 2017 Jan;43(1):117-123. doi: 10.1007/s11239-016-1418-4. J Thromb Thrombolysis. 2017. PMID: 27613177
-
Plasma ADAMTS-13 levels and the risk of myocardial infarction: an individual patient data meta-analysis.J Thromb Haemost. 2015 Aug;13(8):1396-404. doi: 10.1111/jth.13032. Epub 2015 Jul 14. J Thromb Haemost. 2015. PMID: 26073931 Review.
-
Von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura.Semin Thromb Hemost. 2010 Feb;36(1):71-81. doi: 10.1055/s-0030-1248726. Epub 2010 Apr 13. Semin Thromb Hemost. 2010. PMID: 20391298 Review.
Cited by
-
The Role of the Coagulation System in Peripheral Arterial Disease: Interactions with the Arterial Wall and Its Vascular Microenvironment and Implications for Rational Therapies.Int J Mol Sci. 2022 Nov 29;23(23):14914. doi: 10.3390/ijms232314914. Int J Mol Sci. 2022. PMID: 36499242 Free PMC article. Review.
-
ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease.Adv Pharmacol. 2022;94:255-363. doi: 10.1016/bs.apha.2021.11.002. Epub 2022 Jan 24. Adv Pharmacol. 2022. PMID: 35659374 Free PMC article.
-
Circulating ADAMTS13 Levels Are Associated with an Increased Occurrence of Obstructive Sleep Apnea.Dis Markers. 2022 Mar 29;2022:1504137. doi: 10.1155/2022/1504137. eCollection 2022. Dis Markers. 2022. PMID: 35392493 Free PMC article.
-
Blood Group O Protect End-Stage Renal Disease Patients With Dialysis From Coronary Artery Disease.Front Cardiovasc Med. 2022 Jan 28;8:821540. doi: 10.3389/fcvm.2021.821540. eCollection 2021. Front Cardiovasc Med. 2022. PMID: 35155621 Free PMC article.
-
Association between ADAMTS13 deficiency and cardiovascular events in chronic hemodialysis patients.Sci Rep. 2021 Nov 24;11(1):22816. doi: 10.1038/s41598-021-02264-5. Sci Rep. 2021. PMID: 34819564 Free PMC article.
References
-
- Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost. 2006;4:1186–93. - PubMed
-
- Whincup PH, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GD. von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J. 2002;23:1764–70. - PubMed
-
- Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387–97. - PubMed
-
- Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD, Jr, Ginsburg D, Tsai HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413:488–94. - PubMed
-
- Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276:41059–63. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
